Patents Represented by Attorney, Agent or Law Firm Anne M. Rosenblum
-
Patent number: 7842298Abstract: The present invention relates to a novel isolated avian hepatitis E virus having a nucleotide sequence set forth in SEQ ID NO:1 or its complementary strand. The invention further concerns immunogenic compositions comprising this new virus or recombinant products such as the nucleic acid and vaccines that protect an avian or mammalian species from viral infection or hepatitis-splenomegaly syndrome caused by the hepatitis E virus. Also included in the scope of the invention is a method for propagating, inactivating or attenuating a hepatitis E virus comprising inoculating an embryonated chicken egg with a live, pathogenic hepatitis E virus and recovering the virus or serially passing the pathogenic virus through additional embryonated chicken eggs until the virus is rendered inactivated or attenuated.Type: GrantFiled: July 22, 2009Date of Patent: November 30, 2010Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Xiang-Jin Meng, Gholamreza Haqshenas, Fang-Fang Huang
-
Patent number: 7582303Abstract: The present invention relates to a novel isolated avian hepatitis E virus having a nucleotide sequence set forth in SEQ ID NO:1 or its complementary strand. The invention further concerns immunogenic compositions comprising this new virus or recombinant products such as the nucleic acid and vaccines that protect an avian or mammalian species from viral infection or hepatitis-splenomegaly syndrome caused by the hepatitis E virus. Also included in the scope of the invention is a method for propagating, inactivating or attenuating a hepatitis E virus comprising inoculating an embryonated chicken egg with a live, pathogenic hepatitis E virus and recovering the virus or serially passing the pathogenic virus through additional embryonated chicken eggs until the virus is rendered inactivated or attenuated.Type: GrantFiled: July 19, 2005Date of Patent: September 1, 2009Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Xiang-Jin Meng, Gholamreza Haqshenas, Fang-Fang Huang
-
Patent number: 7005130Abstract: The present invention relates to a novel isolated avian hepatitis E virus having a nucleotide sequence set forth in SEQ ID NO:1 or its complementary strand. The invention further concerns immunogenic compositions comprising this new virus or recombinant products such as the nucleic acid and vaccines that protect an avian or mammalian species from viral infection or hepatitis-splenomegaly syndrome caused by the hepatitis E virus. Also included in the scope of the invention is a method for propagating, inactivating or attenuating a hepatitis E virus comprising inoculating an embryonated chicken egg with a live, pathogenic hepatitis E virus and recovering the virus or serially passing the pathogenic virus through additional embryonated chicken eggs until the virus is rendered inactivated or attenuated.Type: GrantFiled: December 31, 2001Date of Patent: February 28, 2006Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Xiang-Jin Meng, Gholamreza Haqshenas, Fang-Fang Huang
-
Preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors
Patent number: 6825352Abstract: Ortho-sulfonamido aryl hydroxamic acids are provided which are useful, inter alia, for the inhibition of matrix metalloproteinases and the treatment of conditions associated with overexpression of MMPs.Type: GrantFiled: August 30, 2002Date of Patent: November 30, 2004Assignee: WyethInventors: Frances Christy Nelson, Arie Zask, James Ming Chen, Dominick Mobilio, Ramaswamy Nilakantan -
Patent number: 6825354Abstract: Compounds of the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.Type: GrantFiled: November 13, 2001Date of Patent: November 30, 2004Assignee: Wyeth Holdings CorporationInventors: Jeremy I. Levin, Aranapakam M. Venkatesan, Derek C. Cole, James M. Chen, Jamie M. Davis, George T. Grosu
-
Patent number: 6593087Abstract: This invention describes novel purified and isolated nucleic acid molecules or the fragments thereof, extracted from nematode or arthropod pests or recombinant, which encode P-glycoprotein homologs and regulate resistance to the macrocyclic lactone compounds. The invention further relates to the new P-glycoprotein homolog expression product of these nucleic acids. Also described herein are methods for detecting the gene encoding for resistance to the macrocyclic lactone compounds in nematode or arthropod pests which comprise comparing the nucleic acids extracted from a pest specimen to the nucleic acids encoding for resistance and the nucleic acids encoding for susceptibility to the macrocyclic lactone compounds.Type: GrantFiled: December 27, 2000Date of Patent: July 15, 2003Assignee: McGill UniversityInventors: Roger K. Prichard, Ming Xu, Ana Paula Ribeiro, William J. Blackhall, Robin N. Beech, Marcelo Molento, Hao Yuan Liu
-
Patent number: 6407217Abstract: The present invention provides an imidazolinone hapten having the structural formula Further provided are an antigen and an enzyme conjugate which are prepared from the imidazolinone hapten. The haptens, antigens and enzyme conjugates provided are useful in immunoassays for determining the presence and concentration of an imidazolinone compound in the presence of one or more other imidazolinone compounds.Type: GrantFiled: January 16, 1997Date of Patent: June 18, 2002Assignee: American Cyanamid CompanyInventors: Rosie Bick-Har Wong, Joseph Luke Pont, Alvin Donald Crews, Jr.
-
Patent number: 6403308Abstract: This invention describes novel purified and isolated nucleic acid molecules or the fragments thereof, extracted from nematode or arthropod pests or recombinant, which encode P-glycoprotein homologs and regulate resistance to the macrocyclic lactone compounds. The invention further relates to the new P-glycoprotein homolog expression product of these nucleic acids. Also described herein are methods for detecting the gene encoding for resistance to the macrocyclic lactone compounds in nematode or arthropod pests which comprise comparing the nucleic acids extracted from a pest specimen to the nucleic acids encoding for resistance and the nucleic acids encoding for susceptibility to the macrocyclic lactone compounds.Type: GrantFiled: April 28, 1998Date of Patent: June 11, 2002Assignee: McGill UniversityInventors: Roger K. Prichard, Ming Xu, Ana Paula Ribeiro, William J. Blackhall, Robin N. Beech, Marcelo Molento, Hao Yuan Liu
-
Patent number: 6231871Abstract: The present invention relates generally to modified microorganisms suitable for use as live in ovo vaccines for avian species. The live in ovo vaccines of the present invention are useful for inducing immunity before or immediately after hatching against a virulent form of the modified microorganism or a microorganism immunologically related to the modified microorganism or a virulent organism or virus carrying an antigenic determinant expressed by the modified microorganism in the live vaccine. The subject live in ovo vaccines are particularly efficacious in enhancing the survival rate of newly-hatched poultry birds.Type: GrantFiled: May 6, 1996Date of Patent: May 15, 2001Assignee: American Cyanamid CompanyInventor: Peter John Coloe
-
Patent number: 6114376Abstract: This invention describes methods for increasing the toxicity of a cytostatic hydrophobic chemotherapeutic agent against resistant tumor cells in mammals which comprise administering a multidrug resistant reversing agent to the mammal in connection with the administration of the cytostatic hydrophobic chemotherapeutic agent in an amount effective to increase the toxicity of the chemotherapeutic agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound. Examples of the macrocyclic lactone compounds useful in the present invention include, but are not limited to, the LL-F28249.alpha.-.lambda. series of compounds, the 23-oxo or 23-imino derivative thereof, the avermectins, the 22,23-dihydro derivatives thereof and the milbemycins. Compositions comprising the macrocyclic lactone compounds and the chemotherapeutic agents are also described herein.Type: GrantFiled: April 28, 1998Date of Patent: September 5, 2000Assignee: McGill UniversityInventors: Roger K. Prichard, Jean-Fran.cedilla.ois Pouliot, Elias Georges
-
Patent number: 6110901Abstract: The present invention relates to methods for controlling and/or treating RNA-replicating viral infections which afflict human beings, animals and/or plants. Specifically, the RNA chain terminating agents, 3'-deoxyribouracil, 3'-deoxyriboguanine and 3'-deoxyribocytosine are useful in treating RNA-replicating viral infections.Type: GrantFiled: February 19, 1992Date of Patent: August 29, 2000Assignee: American Cyanamid CompanyInventors: Yakov Gluzman, Michael Ostrander
-
Patent number: 6010999Abstract: The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing said derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.Type: GrantFiled: June 2, 1995Date of Patent: January 4, 2000Assignee: American Cyanamid CompanyInventors: Michael Joseph Daley, Brian Lee Buckwalter, Susan Mancini Cady, Hong-Ming Shieh, Peter Bohlen, Andrew P. Seddon
-
Patent number: 5951972Abstract: The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing the derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.Type: GrantFiled: February 6, 1995Date of Patent: September 14, 1999Assignee: American Cyanamid CompanyInventors: Michael Joseph Daley, Brian Lee Buckwalter, Susan Mancini Cady, Hong-Ming Shieh, Peter Bohlen, Andrew P. Seddon
-
Patent number: 5877004Abstract: This invention relates to a method for identifying non-essential genes of the human cytomegalovirus (HCMV) genome through the insertion of a .beta.-glucuronidase marker gene into a specified HCMV gene, such that, if the product of the HCMV gene is not expressed, the gene is identified as non-essential for replication of HCMV. This invention also relates to a method of screening for compounds which inhibit HCMV by the insertion of the .beta.-glucuronidase marker gene into a HCMV gene, such that the enzyme marker is expressed and cleaves a conjugate chemical substrate in an assay system to yield a detectable fluorescing product or to result in a color change. This invention further provides the gene responsible in HCMV early cytopathic effect.Type: GrantFiled: June 5, 1995Date of Patent: March 2, 1999Assignee: American Cyanamid CompoundInventors: Thomas R. Jones, Viera P. Muzithras, Yakov Gluzman
-
Patent number: 5866410Abstract: The present invention describes a purified and isolated nucleic acid molecule which encodes for the biosynthetic pathway of tetracycline, chlortetracycline or an analogue thereof. The invention relates to the isolation and cloning of the nucleic acid molecule in an isolated fragment from Streptomyces aureofaciens and the expression of the biosynthetic gene in a heterologous host such as Streptomyces lividans.Type: GrantFiled: June 7, 1995Date of Patent: February 2, 1999Assignee: American Cyanamid CompanyInventors: Michael J. Ryan, Jason A. Lotvin, Nancy Strathy, Susan E. Fantini
-
Patent number: 5843637Abstract: This invention relates to a method for identifying non-essential genes of the human cytomegalovirus (HCMV) genome through the insertion of a .beta.-glucuronidase marker gene into a specified HCMV gene, such that, if the product of the HCMV gene is not expressed, the gene is identified as non-essential for replication of HCMV. This invention also relates to a method of screening for compounds which inhibit HCMV by the insertion of the .beta.-glucuronidase marker gene into a HCMV gene, such that the enzyme marker is expressed and cleaves a conjugate chemical substrate in an assay system to yield a detectable fluorescing product or to result in a color change. This invention further provides the gene responsible in HCMV early cytopathic effect.Type: GrantFiled: June 5, 1995Date of Patent: December 1, 1998Assignee: American Cyanamid CompanyInventors: Thomas R. Jones, Viera P. Muzithras, Yakov Gluzman
-
Patent number: 5807550Abstract: The present invention is directed to antibodies, in particular monoclonal antibodies, which specifically bind to somatotropin binding proteins of animals, but not with the corresponding somatotropin receptors. The antibodies may be used alone to enhance the growth of animals, or may be used together with somatotropin to potentiate the effect of somatotropin in animals. The antibodies may also be used to assay the level of somatotropin binding protein of animals.Type: GrantFiled: June 5, 1995Date of Patent: September 15, 1998Assignee: American Cyanamid CompanyInventors: William Robert Baumbach, Bosco Shang Wang, Homayoun Sadeghi, John Steele Logan, Ian C. Hart
-
Patent number: 5703209Abstract: This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a .beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of .beta.-amyloid protein.Type: GrantFiled: June 5, 1995Date of Patent: December 30, 1997Assignee: American Cyanamid CompanyInventors: Michael Peter Vitek, Jack Steven Jacobsen
-
Patent number: 5693478Abstract: This disclosure concerns a method of detecting the presence of a polypeptide in a sample wherein the polypeptide is encoded by a fragment of a nucleic acid molecule encoding an amyloid precursor mutein and the fragment comprises a sequence encoding at least one marker and a sequence encoding about 419 amino acid residues of the APP-695 isoform, about 475 amino acid residues of the APP-751 isoform or about 494 amino acid residues of the APP-770 isoform. The method encompasses contacting the sample with an antibody, which specifically binds the marker or the amyloid precursor mutein, under suitable conditions to favor the formation of an antibody-antigen complex and detecting the presence of any complex thus formed. The disclosure also deals with the method employing the above nucleic acid fragment wherein the amino acid residues from position 11 to position 28 are deleted from the portion of the sequence encoding the .beta.Type: GrantFiled: June 5, 1995Date of Patent: December 2, 1997Assignee: American Cyanamid CompanyInventors: Michael Peter Vitek, Jack Steven Jacobsen
-
Patent number: RE37741Abstract: The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of non-typable Haemophilus influenzae infection.Type: GrantFiled: June 21, 2000Date of Patent: June 11, 2002Assignee: American Cyanamid CompanyInventor: Gary W. Zlotnick